Literature DB >> 10837172

Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection.

W Chehadeh1, J Weill, M C Vantyghem, G Alm, J Lefèbvre, P Wattré, D Hober.   

Abstract

The activation of the interferon (IFN)-alpha system and its relationship with coxsackievirus B (CVB) infection has been analyzed in 56 patients with insulin-dependent diabetes mellitus (IDDM; 25 children and 31 adults). Elevated levels of IFN-alpha were found in plasma of 70% of patients (39/56), and a positive detection of IFN-alpha mRNA in blood cells by reverse transcriptase-polymerase chain reaction (RT-PCR) was observed in 75% of patients (42/56). Enterovirus (EV) RNA assayed by seminested RT-PCR was detected in the blood of 50% of IFN-alpha-positive patients but not in any IFN-alpha-negative patients. The results of genotype analysis of amplified EV RNA sequences (5 CVB2, 8 CVB3, and 8 CVB4) were concordant with the results of CVB-neutralization tests. The comparison between IFN-alpha, EV RNA, and serology suggested that the proportion of CVB infection associated with IFN-alpha positivity might be higher than is predicted from the investigation of EV RNA. Together, the results suggest that, in a majority of cases, a CVB infection is associated with clinical IDDM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837172     DOI: 10.1086/315516

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Persistent infection of human thymic epithelial cells by coxsackievirus B4.

Authors:  Fabienne Brilot; Wassim Chehadeh; Chantal Charlet-Renard; Henri Martens; Vincent Geenen; Didier Hober
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in beta cells.

Authors:  W Chehadeh; J Kerr-Conte; F Pattou; G Alm; J Lefebvre; P Wattré; D Hober
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Human enterovirus infections in children at increased risk for type 1 diabetes: the Babydiet study.

Authors:  M-L Simonen-Tikka; M Pflueger; P Klemola; C Savolainen-Kopra; T Smura; S Hummel; S Kaijalainen; K Nuutila; O Natri; M Roivainen; A-G Ziegler
Journal:  Diabetologia       Date:  2011-09-20       Impact factor: 10.122

Review 4.  Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host.

Authors:  Didier Hober; Pierre Sauter
Journal:  Nat Rev Endocrinol       Date:  2010-03-30       Impact factor: 43.330

5.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

Review 6.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

7.  Total chemical synthesis of human interferon alpha-2b via native chemical ligation.

Authors:  Jing Li; Clara Lehmann; Xishan Chen; Fabio Romerio; Wuyuan Lu
Journal:  J Pept Sci       Date:  2015-03-24       Impact factor: 1.905

8.  Persistent infection of thymic epithelial cells with coxsackievirus B4 results in decreased expression of type 2 insulin-like growth factor.

Authors:  Hela Jaïdane; Delphine Caloone; Pierre-Emmanuel Lobert; Famara Sane; Olivier Dardenne; Philippe Naquet; Jawhar Gharbi; Mahjoub Aouni; Vincent Geenen; Didier Hober
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

Review 9.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

10.  Coxsackievirus B4 infection of human fetal thymus cells.

Authors:  Fabienne Brilot; Vincent Geenen; Didier Hober; Cheryl A Stoddart
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.